SCHEMBL1665531

SCHEMBL1665531

O=C1C=C(CC(F)(F)F)C(O)O1

nearest known ligand 0.36

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 3/20 0.33
PTGS2 P35354 3/20 0.33
HMGCR P04035 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9482405 0.75
SCHEMBL9812598 0.74
SCHEMBL364135 0.74
SCHEMBL7363051 0.69 ALOX5 (0.38) ALOX5PTGS2HMGCR
SCHEMBL9838225 0.68 ALOX5 (0.37) ALOX5PTGS2HMGCR
SCHEMBL18748184 0.67 CALM1 (0.38)
SCHEMBL9483546 0.67 ALOX5 (0.32) ALOX5PTGS2HMGCR
SCHEMBL9483555 0.67 ALOX5 (0.32) ALOX5PTGS2HMGCR
SCHEMBL17236310 0.66
SCHEMBL10577585 0.66 ACHE (0.39) ALOX5PTGS2HMGCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3790885-B1 1-IMIDAZOTHIADIAZOLO-2H-PYRROL-5-ONE DERIVATIVES UCB Biopharma SRL (BE) 2023-04-19 EP disclosed
US-11286266-B2 1-imidazothiadiazolo-2H-pyrrol-5-one derivatives UCB Biopharma SRL 2022-03-29 US disclosed
US-20210107922-A1 1-IMIDAZOTHIADIAZOLO-2H-PYRROL-5-ONE DERIVATIVES UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) 2021-04-15 US disclosed
US-20210107922-A1 1-IMIDAZOTHIADIAZOLO-2H-PYRROL-5-ONE DERIVATIVES UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) 2021-04-15 US disclosed
EP-3790885-A1 1-IMIDAZOTHIADIAZOLO-2H-PYRROL-5-ONE DERIVATIVES UCB Biopharma SRL (BE) 2021-03-17 EP disclosed
CN-112088160-A 1-imidazothiadiazol-2H-pyrrol-5-one derivatives UCB生物制药有限责任公司 2020-12-15 CN disclosed
WO-2019215062-A1 1-IMIDAZOTHIADIAZOLO-2H-PYRROL-5-ONE DERIVATIVES UCB BIOPHARMA SPRL (BE) 2019-11-14 WO disclosed
WO-2019215062-A1 1-IMIDAZOTHIADIAZOLO-2H-PYRROL-5-ONE DERIVATIVES UCB BIOPHARMA SPRL (BE) 2019-11-14 WO disclosed
US-8586623-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2013-11-19 US disclosed
US-8586623-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2013-11-19 US disclosed
US-20090312333-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses UCB PHARMA, S.A. (BE) 2009-12-17 US disclosed
US-20090312333-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses UCB PHARMA, S.A. (BE) 2009-12-17 US disclosed
US-20090312333-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses UCB PHARMA, S.A. (BE) 2009-12-17 US disclosed
US-20090156607-A1 2-OXO-1-PYRROLIDINE DERIVATIVES UCB, S.A. (BE) 2009-06-18 US disclosed
US-20090156607-A1 2-OXO-1-PYRROLIDINE DERIVATIVES UCB, S.A. (BE) 2009-06-18 US disclosed
US-20090156607-A1 2-OXO-1-PYRROLIDINE DERIVATIVES UCB, S.A. (BE) 2009-06-18 US disclosed
EP-1912966-A2 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB, S.A. (BE) 2008-04-23 EP disclosed
EP-1891042-A2 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB Pharma, S.A. (BE) 2008-02-27 EP disclosed
WO-2006128692-A2 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB PHARMA, S.A. (BE) 2006-12-07 WO disclosed
WO-2006128693-A2 2 -OXO-I -PYRROLIDINE DERIVATIVES/ PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB PHARMA, S.A. (BE) 2006-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11286266-B2 1-imidazothiadiazolo-2H-pyrrol-5-one derivatives TPMT, THPO, PKD1 ALOX5 2775/4885PTGS2 515/4885HMGCR 2069/4885
US-20090312333-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses CYP3A4, CYP1B1, CYP2D6 ALOX5 1045/4885PTGS2 215/4885HMGCR 989/4885
US-20210107922-A1 1-IMIDAZOTHIADIAZOLO-2H-PYRROL-5-ONE DERIVATIVES TPMT, THPO, PKD1 ALOX5 2775/4885PTGS2 515/4885HMGCR 2069/4885
US-20090156607-A1 2-OXO-1-PYRROLIDINE DERIVATIVES OPRD1, PPOX, CYP2D6 ALOX5 1550/4885PTGS2 115/4885HMGCR 1607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.